PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
25653183-13	2015	AngII-induced tenascin-C expression and vascular remodelling were abolished by celecoxib and by mPGES-1 deletion.	Celecoxib	79-88	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	0-5	
26856544-10	2016	Celecoxib treatment also decreased AngII-induced macrophage infiltration and TNF-alpha expression.	Celecoxib	0-9	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	35-40	
23209546-5	2012	Celecoxib treatment that was started 1 week after initiating AngII infusion reduced AAA incidence by 61% and significantly decreased AAA severity.	Celecoxib	0-9	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	61-66	
22671943-3	2013	RESULTS: Apocynin, Mito-TEMPO, and Celecoxib treatments prevented Ang II-induced hypertension, the increased vasoconstrictor responses to phenylephrine, and the reduced acetylcholine relaxation.	Celecoxib	35-44	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	66-72	
22671943-8	2013	Apocynin, Mito-TEMPO, and Celecoxib improved the diminished nitric oxide (NO) production and the modulation by NO of phenylephrine responses in the Ang II model.	Celecoxib	26-35	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	148-154	
16514081-0	2006	Selective cyclooxygenase-2 inhibition with celecoxib decreases angiotensin II-induced abdominal aortic aneurysm formation in mice.	Celecoxib	43-52	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	63-77